Navigation Links
EMA Starts Formal Review of Glybera(R) Dossier
Date:1/25/2010

pectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. AMT Starts Preregistration Trial for Glybera(TM)
3. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
4. BioCis Pharma Starts Phase IIa Trial in Psoriasis
5. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
6. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
11. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... latest developments, patents and results of studies and trials. ... Lilly and Company (NYSE: LLY ), Gilead ... (NASDAQ: CELG ) and Arena Pharmaceuticals Inc. ... leader in developing prodrug therapeutics for the treatment of ...
(Date:9/19/2014)... September 19, 2014 , The ... Society for Paediatric Endocrinology (ESPE) Meeting  Investment ... medical research in the field of growth  , ... Germany , today announced the first ... 2014. The awards were announced during a Satellite Symposium ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... 2010 Regenicin , Inc. (OTC Bulletin Board: ... of regenerative cell therapies to restore the health of damaged ... placement. Regencin secured proceeds of $467,550.25. In addition the company ... net of placement agent fees and expenses, will be used ...
... Intarcia Therapeutics. Inc today announced that Kurt Graves, ... at the Lazard Capital Markets 7th Annual Healthcare ... November 16, 2010 at 1:40pm local time at ... (Logo:   http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO ) (Logo: ...
... today announced the receipt of a two-year Small Business ... the National Institute on Aging, National Institutes of Health ... antibodies targeting tau protein oligomers in the development of ... be screened at the Michigan High Throughput Screening Center ...
Cached Biology Technology:Regenicin Announces Closing of Private Placement Transaction 2Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference 2Oligomerix, Inc. Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer's Disease 2
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... Dogs generally seem to be cheerful, happy-go-lucky characters, so ... outlook on life. , In fact some dogs ... University of Sydney shows. , "This research is ... in dogs objectively and non-invasively. It offers researchers and ... and how that changes," said Dr Melissa Starling, from ...
(Date:9/18/2014)... nitrogen comprise all spheres of our planet. Manifold ... imbalances and perturbations that resulted in increases of ... in climate changes which influence the complex biogeochemical ... Understanding these feedback mechanisms has become an important ... the past three decades. , In parallel, a ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Dogs can be pessimists too 2Dogs can be pessimists too 3Greenhouse gas research enters a new era 2
... and muscles around the mouth plays an important role not only ... in the way they are heard according to a study by ... your own face is moving makes a difference in how you ... scientist at Haskins. When, Ito and his colleagues used a ...
... University political science professor is working with Southern ... trade agreements that could threaten the world,s food ... Thompson has been consulting on international agriculture trade ... living in Southern African countries studying agricultural expertise ...
... that face mankind and the environment, there is ... policy, business and education that new, more integrative ... interdisciplinary and multidisciplinary approaches to solving problems at ... at the institutional level. , Integrated Science − ...
Cached Biology News:Feeling your words: Hearing with your face 2New book plants seed for biodiverse food production 2New book plants seed for biodiverse food production 3
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: